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Background: In chronic heart failure (CHF), it remains unclear whether the minimal dose of beta-blockade is
related to survival beneﬁts and which parameter predicts morbidity and mortality. We sought to determine
the minimal dose related to survival beneﬁts by comparing the efﬁcacy and safety of three doses of carvedilol
and the best predictive parameter for effective outcomes in Japanese patients with CHF.
Methods: In this prospective, randomized, stratiﬁed trial, 364 patients with mild to moderate CHF were
assigned to a daily carvedilol dose of 2.5, 5, or 20 mg, plus optimal standard therapy.
Findings: During the mean 3-year follow-up, resting heart rate (HR) and BNP were signiﬁcantly reduced with
dose–response relations in the early period but without dose–response relations in the late period. The LVEF
and the LVDd were increased and decreased, respectively, without a dose–response relation. No signiﬁcant
difference was seen in the composite primary endpoint of all-cause mortality and hospitalization for cardio-
vascular diseases and heart failure. Multivariate analysis indicated early decreases in HR and BNP predicted
long-term outcomes. However, adverse events increased dose-dependently. Among 237 polymorphisms in
87 heart failure-related genes, the osteopontin G-156 del genotype was associated with an event-free survival
rate (Wilcoxon test, P=0.030).
Conclusions:A low carvedilol dose is effective if the HR and/or plasma BNP has been reduced. Carvedilol therapy
should be guided by reductions in HR and/or BNP, especially by initial HR reduction, but not only by its dose.
OPN might be a surrogate genetic marker for long-term event-free survival.© 2012 Elsevier Ireland Ltd. Open access under CC BY-NC-ND license. rate; BNP, brain natriuretic peptide; LV, left ventricular; OPN, osteopontin; MUCHA, the Multicenter Carvedilol Heart Failure
rvedilol Heart Failure Assessment trial; BEST, the Beta-Blocker Evaluation of Survival trial; beta1ARArg, beta 1 adrenergic
tion; NYHA, New York Heart Association; SAS, speciﬁc activity scale; ECG, electrocardiogram; CVD, cardiovascular diseases;
ft ventricular ejection fraction; LVDd, LV diastolic diameter; MERIT-HF, Metoprolol CR/XL Randomized Intervention Trial in
ciency Bisoprolol Study II trial; COPERNICUS, the Carvedilol Prospective Randomized Cumulative Survival trial NT-proBNP,
vedilol ACE-Inhibitor Remodeling Mild CHF EvaluatioN trial; RUNX2, Runt-related transcription factor 2; BMI, body mass
ressure; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker.
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For patients with chronic heart failure (CHF) resulting from left ven-
tricular (LV) systolic dysfunction, beta-blockade improves clinical out-
comes [1,2] and is therefore recommended in key treatment guidelines
[3–5]. In the clinical setting, dose-escalation therapy beginning at a low
dose has been applied according to these key guidelines. The established
target daily carvedilol dose is usually 50 mg, occasionally 100 mg, in the
United States and Europe. Despite guideline recommendations, pre-
scribed doses are often lower than those shown to reduce morbidity
and mortality in clinical trials [6,7]. In the Multicenter Carvedilol Heart
Failure Dose Assessment (MUCHA) study, morbidity improved even at
carvedilol daily doses of 5 mg and 20 mg, as compared to a placebo [8].
For the treatment of hypertension in Japan, one-third or one-half of the
dose used in the United States and Europe has been recommended
[9], probably because of ethnic differences contributing to a better
responsiveness to beta-blockers [10,11]. Moreover, the Multicenter
Oral Carvedilol Heart Failure Assessment (MOCHA) trial [12] found a
dose-dependent decrease in mortality and cardiovascular hospitaliza-
tion; however, the differences in the outcomes between doses were
minimal during the six-month follow-up. Further, no report has been
published comparing the efﬁcacy of different doses for identifying the
minimal effective dose. In a recent meta-analysis, the survival beneﬁt
of beta-blockade was demonstrated to be associated with the degree
of heart rate reduction, while no signiﬁcant relationship was observed
between beta-blocker doses and the improvement of all-cause mortal-
ity [13,14]. Moreover, heart rate reduction itself signiﬁcantly reduced
major risks associated with heart failure [15,16]. However, whether
the beneﬁts of beta-blockade are related to the administered dose or
the degree of heart rate reduction remains unclear. As well, the ethnic
or individual genetic background likely determines the clinical outcome
of beta-blocker drugs, as genetic variants have been shown tomodify the
responsiveness to beta-blockade [17]. For instance, the Beta-Blocker
Evaluation of Survival (BEST) substudy revealed that beta1ARArg389 ho-
mozygotes treatedwith bucindolol had a lowermortality risk than those
treated with the placebo [18].
In the present study, we prospectively examinedwhether the clinical
outcome of carvedilol was related to the administered dose or the heart
rate reduction, and whether the minimal dose of carvedilol provided a
survival beneﬁt. To accomplish this aim, we evaluated event-free surviv-
al by intention-to-treat analysis in response to carvedilol treatment by
comparing the efﬁcacy and safety of 3 doses of carvedilol in Japanese pa-
tients with CHF. In addition, we assessed different surrogate markers to
determine which ones were predictive of drug efﬁcacy, including heart
rate, brain natriuretic peptide (BNP), ejection fraction (EF), New York
Heart Association (NYHA) functional class, and other clinical parameters.
2. Methods
2.1. Study design and patient recruitment
The J-CHF study was approved by the Ethics Committee of Hokkaido University
Graduate School of Medicine, Hokkaido, Japan, and complies with the Declaration of
Helsinki. The institutional review board of each participating institution approved
the J-CHF study protocol, including the pharmaco-genomic analyses. The authors
have certiﬁed that they comply with the Principles of Ethical Publishing in the Interna-
tional Journal of Cardiology.
Between July 2003 and January 2008, 364 patientswere registered at 130 clinical sites
in Japan using an internet-based entry system. Using centralized, computer-generated
randomization with an algorithm based on the underlying disease, severity, age, and
sex, the 364 patientswere randomly allocated using a 1:1:1 ratio to one of three carvedilol
groups (2.5 mg, 5 mg, or 20 mg daily). Other beta-blockers were prohibited, as were
α-blockers, αβ-blockers, and inotropic agents other than digitalis. Consent for this study
was given by all patients enrolled in this study, while consent for the pharmaco-
genomic study was obtained from 126 patients. Inclusion criteria were stable CHF
(NYHA class II/III, EF≤40%), not currently taking carvedilol, and an age between 20 and
80 years. Exclusion criteria were the same as in the MUCHA study [8].
The study design is outlined in Fig. 1. Following an 8-week observation period, car-
vedilol was titrated upward over an 8-week period from 1.25 mg twice daily to the tar-
get dose of 10 mg twice daily based on tolerability. Thereafter, patients were seenevery 2 to 8 weeks for the 3-year follow-up. Every 6 months, patients were evaluated
for NYHA class and speciﬁc activity scale (SAS). In addition, an ECG, chest X-ray, echo-
cardiography, and lab tests including BNP were conducted at weeks 0, 24, and 48 of the
ﬁxed-dose period. Of the 364 eligible patients, 4 withdrew informed consent, 8 were
lost to follow-up, and 352 patients were maintained at the randomly assigned dose
or the maximum tolerated dose below the target dose for the study duration and
were available for analyses by treatment allocation (Fig. 2).
2.2. Primary and secondary endpoints
The primary endpoint was the composite of all-cause mortality and hospitalization
for cardiovascular diseases (CVD) and heart failure. All the clinical data were collected
at an independent core lab of the Administration Ofﬁce. Study endpoints and all out-
comes were assessed by an independent and blinded Endpoints Committee and then
statistically evaluated in an independent Monitoring Ofﬁce. The secondary endpoints
were all-cause mortality, hospitalization for CVD or heart failure, or worsening of
symptoms (deﬁned as a decrease ≥1 Mets in the questionnaire score or an increase
≥1 NYHA class for at least 3 months) or a need for modiﬁcation of heart failure treat-
ment (changes in oral medicine for at least one month or addition of intravenous
inotropes for at least 4 h).
2.3. Genetic polymorphisms
Genomic DNA was extracted from peripheral blood leukocytes using the QIAamp
DNA Blood Maxi Kit (QIAGEN, Hilden, Germany). Eighty-seven heart failure-related
genes and 237 polymorphisms were selected as detailed in Appendix 3. The genotyping
of each polymorphism was performed by PCR-based methods. The OPN gene polymor-
phisms were determined by sequencing with the ABI PRISM BigDye Terminator Cycle Se-
quencing Ready Reaction Kit (Applied Biosystems, Foster City, USA).
2.4. Sample size
The sample size was based on a signiﬁcance level of α=0.04 for all-cause mortality
and hospitalizations for CVD or heart failure (two-sided, by treatment allocation) with
80% power (βb0.20) to detect differences between treatment groups for the primary end-
point, we calculated that we needed to recruit 450 patients. Using the results from the
MUCHA study in Japanese patients as a guide, we set the event incidence rate in the
5-mg and 20-mg groups at 9% and 6%, respectively. The event incidence rate for the
2.5-mg group was set at 15%, based on a separate hyperbolic graph. During the time
frame of the J-CHF study, carvedilol became the standard treatment for heart failure. Con-
sequently it became increasingly difﬁcult to recruit patientswhowerenot taking thedrug.
In March 2007, the Executive Committee extended the length of the ﬁxed dose mainte-
nance phase from 24 weeks to 48 weeks and the follow-up period from 26 weeks until
a sufﬁcient number of events had occurred, thereby reducing the number of patients re-
quired to 420. Two interim analyses were planned when the study length was extended.
The predeﬁned stopping rule for efﬁcacywas based on the occurrence of primary outcome
events, analyzed by treatment allocation,with predetermined interim analyseswhen25%,
50%, and 75% of expected primary events had occurred. The study was designed to termi-
nate after the accrual of 97 primary events and aminimumof 4.5 years of follow-up for all
enrolled patients. The ﬁrst interim analysis was performed in December 2006 after 298
patients were enrolled (median follow-up period; 1.56 years, person-time; 420.8 person-
years). A primary event had occurred in 29 patients and the 2-year event-free survival
rate was calculated to be 87.7% (95% CI; 82.6%–91.3%). The second interim analysis was
performed in December 2008. A primary event had occurred in 74 patients. With 2 interim
analyses, the study-wide type I error rate of 0.05 was maintained by allocating α=0.0113
to the analysis of all-cause mortality or hospitalization for CVD or CHF, and α=0.0008 to
the short-term clinical status studies.
2.5. Statistical analysis
Based on survival in the MUCHA trial, event-free survival was assumed to be 85.3%
in the second year of the 2.5-mg/d group. For an 80% power to detect a hazard ratio of
2.0 in the 5-mg or 20-mg groups using the log-rank test and a signiﬁcance level of 2.5%
(one-sided), a sample size of 417 (139 per treatment group) was required. For the
main analyses, we used the log-rank test to compare the three groups, and the Cox
hazards model to calculate hazard ratios and 95% conﬁdence intervals (CI). Cumulative
survival curves were constructed as time-to-ﬁrst-event plots by the Kaplan–Meier
method. For estimating effect size, hazard ratios with 95% CI were calculated using
the Cox regression model. Continuous variables are reported as mean±standard devia-
tion (SD). An α-level of 0.02168 (one-sided) was used to indicate statistical signiﬁcance
for the primary endpoint; an α-level of 0.05 (two-sided), all secondary endpoints. All
analyses were conducted by treatment allocation in accordance with the intention-to-
treat principle. Data were analyzed with the SAS version 9.1 statistical program
(SAS Institute Inc., Cary, NC, USA).
2.6. Role of the funding source
The sponsors of this study played no role in the study design, data collection, data
analysis, data interpretation, the writing of the report, or in the decision to submit the
Fig. 1. Study protocol. The mean up-titration period (from the initiation of carvedilol to a ﬁxed-dose period week 0) was 52.9 days. NYHA, New York Heart Association, SAS, speciﬁc
activity scale; SBP, systolic blood pressure; and BNP, brain natriuretic peptide.
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sponsibility for the decision to submit for publication.
3. Results
In March 2009, based on data from two interim analyses, the study
was terminated because of a statistically equivalent improvement in
survival with carvedilol, exceeding the pre-speciﬁed interim monitor-
ing boundaries for all three treatment groups. The safety parameters
were similar among the groups. Furthermore, the Data and SafetyMon-
itoring Committee deemed this ﬁnding clinically important, since it was
the ﬁrst demonstration that low-dose carvedilol is safe and effectively
reduces all-causemortality or hospitalization, and thus could not be de-
nied to patients outside the study.
3.1. Demographics and patient characteristics
The patient demographics and baseline characteristics are shown in
Table 1. CHF was due to ischemia and cardiomyopathy in 29% and 62%
of the patients, respectively. The mean LVEF was 30.2±0.7%. Mean-
while, 83% of patients had NYHA class II heart failure. Chronic atrialFig. 2. J-CHF study proﬁle. The patient ﬂow chart shoﬁbrillation was found in 20.6%, while 12% had a prior coronary artery
bypass graft or a percutaneous coronary intervention. No signiﬁcant dif-
ferences in the key parameters shown in Table 1 were observed be-
tween groups; the drugs used for treating heart failure were similar.3.2. Adverse events
At the completion of the 8-week up-titration, the average daily doses
of carvedilol were 2.4 mg, 4.8 mg, and 16.7 mg in the three treatment
groups. One patient died during this period. Table 2 shows discontinua-
tion or changes in the treatment doses. Gradual dose escalation resulted
in a higher tolerable dose of carvedilol. Only 0.7% of patients in the
2.5-mg group did not tolerate carvedilol, as compared to 4.2% in the
5-mg group (Pb0.05) and 23% in the 20-mg group (Pb0.05). Drug dis-
continuation occurred in only 1.7%, 2.6%, and 3.4% of the patients in the
2.5-mg, 5-mg, and 20-mg groups, respectively. In the 20-mg group, dis-
continuation rate was signiﬁcantly higher due to hypotension or brady-
cardia compared with the 2.5-mg group. More adverse effects related to
hypotension and bradycardia and fewer tachycardia and tachyarrhyth-
mia events occurred in the 20-mg group than in the other two groups.ws that no patients (pts.) were lost to follow-up.
Table 1
Demographics and baseline characteristics of the patients. BMI, body mass index; IHD,
ischemic heart disease; LVEF, left ventricular ejection fraction; SAS, speciﬁc activity
scale; SBP, systolic blood pressure; BNP, brain natriuretic peptide; ACEI, angiotensin-
converting enzyme inhibitor; and ARB, angiotensin II receptor blocker. Data are repre-
sented as the mean±SD or the number of patients (%).
2.5 mg 5 mg 20 mg
n=119 n=121 n=120
Age (yr) 58.8±13.0 61.4±12.1 60.5±12.2
Sex (M/F) 88/31 90/31 89/31
BMI (kg/m2) 24.1±4.4 23.3±3.9 23.4±3.9
NYHA II/III 99/20 100/21 100/20
IHD/non-IHD 29/90 30/91 30/90
LVEF (%) 30.4±7.9 29.9±6.6 30.4±7.0
SAS score (Mets) 5.0±2.3 5.0±2.2 5.2±1.9
SBP (mm Hg) 120.9±21.1 118.6±16.9 120.6±18.0
Heart rate (bmp) 82.6±15.9 79.0±16.0 79.8±17.7
BNP (pg/ml) 337.1±348.8 375.5±409.4 457.2±551.3
Digitalis 33% 32% 33%
Diuretics 90 89 91
Vasodilators 24 42 29
Anti-arrhythmic drugs 12 9 11
ACE/ARB 46/61 44/64 44/58 Fig. 3. Changes in LVEF. The mean LVEF (left ventricular ejection fraction) from the ini-
tiation of carvedilol to the ﬁxed-dose period of weeks 24 and 48 increased without a
dose–response relationship. *Pb0.05 versus the observation period (OP). Values repre-
sent the mean±CI.
Table 3
Multivariate analyses related to the primary endpoint. Compared to the 5-mg group,
the occurrence of the primary endpoint was 14% lower in the 2.5-mg group (P=0.31).
A total of 24 patients died. All cause-death was a secondary endpoint.
Parameters Parameter
estimate
Chi-square
P value
Hazard ratio
(95% CI)
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During the follow-up period, symptoms (NYHA and SAS) improved
equivalently in each group. LV diastolic diameter (LVDd)was decreased
by a signiﬁcant 7.4% at week 24 and 8.7% at week 48, without a dose–
response relationship. There was a signiﬁcant 37.7% and 41.7% rela-
tive increase in LVEF at weeks 24 (41.6±1.3) and 48 (42.8±1.4)
of the ﬁxed-dose period from baseline (30.2±0.7), respectively,
without a dose–response relationship. The delta changes in the LVEF be-
tween the observation period and week 24 were equivalent in each
group (Fig. 3). The BNP levels were dose-dependently reduced at week
0 (217.8±247.2 pg/ml). Although BNP levels gradually and relatively
decreased by 60% from baseline (388.8±444.5 pg/ml) at week 48
(156.4±307.9 pg/ml), no differences between doses were observed.
Resting heart rate, based on 12-lead ECG data, was signiﬁcantly reduced
in each group during the ﬁxed-dose period atweek 0 (5.4 bpm, 7.3 bpm,
and 11.0 bpm) with a clear dose–response relationship, at weeks 24
(8.3 bpm, 8.2 bpm, and 12.1 bpm) and 48 (8.7 bpm, 9.7 bpm, and
10.9 bpm) without any signiﬁcant dose–response relationship. Chronic
AF was present in 20.6% of all the patients. There were no signiﬁcant dif-
ferences in age, sex, NYHA class, EF, dose of carvedilol and resting HR be-
tween patientswith AF or sinus rhythm (SR). Restingmean heart rates at
baseline were 78.5 and 81.1 bpm, and reduced to 71.4 and 70.7 bpm at
week48 in theAF and SRpatients, respectively. No signiﬁcant differences
for the primary endpoint were found in both AF and SR patients. There
were signiﬁcant 41.9% and 43.6% relative increases in LVEF at week 48
of theﬁxed-dose period frombaseline in both AF and SRpatients, respec-
tively. Patients with CHF and AF derive comparable clinical beneﬁts from
carvedilol titration as those in SR.Table 2
Discontinuation or changes in the treatment dose. The study protocol deﬁned a serious
adverse event as a fatal or life-threatening event that required or prolonged hospitali-
zation or resulted in a persistent or signiﬁcant disability or incapacity.
Treatment
group
Achieved
dose
No change in
treatment dose
Change in
treatment dose
Discontinuation
2.5 mg 2.4 mg 93% 0.7% 1.7%
5 mg 4.8 mg 90% 4.2% 2.6%
20 mg 16.7 mg 73%⁎ 23%⁎ 3.4%⁎
Total 85% 9.4% 2.6%
⁎ Pb0.05 versus 2.5 mg/d dose.3.4. Effects of carvedilol on primary endpoint
The primary endpoint occurred in 74 patients (20%) during the
mean 3-year follow-up period (Table 3). The occurrence of the prima-
ry endpoint was 14% lower in the 2.5-mg group than that in the 5-mg
group (P=0.31). No signiﬁcant between-group differences for the
primary endpoint were found, as shown by the Kaplan–Meier curve
(Fig. 4). In total, 24 patients died; all cause-death was a secondary
endpoint. NYHA was not related to an increased risk for the primary
endpoint, whereas SAS was weakly correlated. At week 0 of the ﬁxed-
dose period, as compared to the observation period, the BNP and heart
rate were signiﬁcantly related to a decreased risk for the primary end-
point. In fact, a decrease in BNP was associated with a statistically signif-
icant 17% relative risk reduction for the primary endpoint. Change in EF
did not correlate signiﬁcantly, whereas changes in heart rate and BNP
did (Pb0.001). There was a signiﬁcant 12% relative decrease in resting
HR (from 80.6 to 71.2 bpm) at week 48 of the ﬁxed-dose period from
baseline without a dose–response relationship. Resting heart rates
reached below 75 bpm in 66.3% of all patients. Patients with reduced
HR below 75 bpm showed better clinical outcomes as shown in Fig. 5B.
For evaluating the risk of the primary endpoint in relation to changesTreatment (2.5 mg vs. 5 mg) 0.612 0.183 1.844 (0.749–4.536)
Treatment (2.5 mg vs. 20 mg) 0.868 0.056 2.383 (0.977–5.810)
Sex (M/F) 0.518 0.216 1.679(0.738–3.817)
Age (yr) −0.012 0.482 0.988 (0.957–1.021)
LVEF(OP) −0.023 0.422 0.977 (0.925–1.033)
BNP log (OP) 1.397 0.004 4.044 (1.563–10.46)
HR (OP) 0.015 0.344 1.015(0.984–1.047)
NYHA class 0.199 0.658 1.220 (0.507–2.938)
SAS score (Mets) −0.278 0.030 0.757 (0.589–0.974)
ΔLVEF (ﬁxed 24 w−OP) −0.031 0.052 0.969 (0.939–1.000)
ΔBNP log (ﬁxed 0 w−OP) 2.807 b0.000 1 16.56 (4.759–57.61)
ΔHR (ﬁxed 0 w−OP) 0.054 0.002 1.055 (1.020–1.091)
Δ: change.
OP: observation.
Fig. 4. Kaplan–Meier estimate for primary endpoint. The primary endpoint occurred in
74 patients during the mean 3-year follow-up period. No signiﬁcant between-group
differences for the primary endpoint were found.
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ﬁxed-dose periods, a change in trimester distribution was associated
with a reduction in risk at week 0 (Fig. 5A and B). Thus, BNP and heartFig. 5. A and B. Kaplan–Meier estimates for the primary endpoints ΔBNP log and ΔHR. The Ka
BNP, brain natriuretic peptide; and HR, heart rate.rate at week 0 seem to be predictors for the risk of death or hospitaliza-
tion in these patients.
3.5. Genetic polymorphisms
In a Wilcoxon analysis of 237 polymorphisms in 87 genes, only the
OPN G-156 del genotype showed a signiﬁcant relation with the
event-free survival rate (P=0.030) (Fig. 6). Patients with the OPN
del/del genotype showed survival beneﬁts, indicating the OPN del al-
lele is a genetic risk factor for responsiveness to carvedilol. The beta1AR
Arg389Gly, Ser49Gly, and alpha (2C)Del genotypeswere not associated
with event-free survival or heart rate (data not shown), and no signiﬁ-
cant results were observed for these three genotypes for the low-dose
and high-dose groups.
4. Discussion
The J-CHF study with blinded efﬁcacy adjudication revealed no
signiﬁcant differences in the primary endpoint of all-cause mortality
or hospitalization for CVD or heart failure among the three evaluated
carvedilol doses (2.5 mg, 5 mg, and 20 mg). LVEF increased by 41.7%
from the baseline of the ﬁxed-dose period from baseline (from 30.2±
0.7 to 42.8±1.4). Plasma BNP, heart rate, and LVDd were signiﬁcantly
decreased initially in a dose-dependent manner and later in a non-
dose-dependent manner. Notably, a small dose of carvedilol (2.5 mg/d)
provided a similar long-term outcome relative to the higher doses, with
concomitant heart rate reduction and improved LVEF, plasma BNP,plan–Meier plots for the primary endpoints by tertiles of ΔBNP log and ΔHR. Δ, change;
Fig. 6. Association between OPN G-156del polymorphism and event-free survival. Solid
line, del homozygote and broken line, G allele carrier. The two curves were signiﬁcantly
different according to the Wilcoxon test (P=0.030).
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decreases in plasma BNP and heart rate to be clinical predictors of
long-term outcomes. In contrast to dose-independent outcomes, drug
discontinuation and adverse events were dose-dependent. The study
was stratiﬁed with underlying disease, severity, age, and sex and we
used Cox's proportional hazards regression analyses of total mortality
or hospitalization to explore any unfavorable outcome in prespeciﬁed
risk groups, deﬁned by entry characteristics.
Several studies have reported that the mortality beneﬁts of beta-
blockers are dose-dependent, but only the MOCHA study prospective-
ly examined dose-related efﬁcacy, in which carvedilol produced a lin-
ear improvement in LVEF in the 12-mg, 25-mg, and 50-mg groups
and showed reductions inmortality and hospitalization rates compared
with the placebo. However, the median follow-up was only 6 months.
Further, the trialwas designed to evaluate the sub-maximal exercise ca-
pacity as a primary parameter and was not examined for the inﬂuence
of heart rate. Even now, no reports have been published comparing
the efﬁcacy of different doses of carvedilol to identify theminimal effec-
tive dose for heart failure.
Recently, in a post hoc analysis, a higher dose of beta-blockade
was associated with signiﬁcantly lower rates of all-cause death and
all-cause hospitalization [19]. However, there is as yet no deﬁnitive
evidence of a dose–response relationship in a randomized, controlled
trial. It has been demonstrated in the meta-analysis of randomized
heart failure trials that the survival beneﬁt of beta-blockers to be asso-
ciated with the magnitude of heart rate reduction but not with the
dose; a commensurate 18% reduction in the risk of death was obtained
with every heart rate reduction of 5 bpm, while no signiﬁcant relation-
ship was found between all-cause mortality and the beta-blocker dose
[13,14]. Is there any additional beneﬁt to up-titrating beta-blockers to
trial doses if substantial heart rate reduction has already been achieved
even with a lower dose? In the MERIT-HF trial [20], the heart rate
showed a dose-related decrease in the early period, but after 3 months
no signiﬁcant differencewas observed between the low- and high-dose
groups. Total mortality was also similar in these 2 groups. In the J-CHF
trial, the mean heart rate reduction was 8.0, 9.6, and 9.8 bpm at
weeks 0, 24, and 48, respectively, which was compatible with the CIBIS
II trial [21]. As well, a reduction in risk was reﬂected by early changes
in the mean heart rate reduction. The linear dose-dependency of the
heart rate reduction disappeared at weeks 24 and 48. Thus, initial
changes in heart rate might predict the clinical outcome after long-
term treatment with carvedilol, and it is suggested that even at
2.5 mg/d of carvedilol, if the heart rate has been reduced, the clinical
outcome is improved. Still, the J-CHF trial is the only one to compare
the effect of the dose from the perspective of heart rate reduction,
which may correspond to the results of the meta-analysis.At the completion of the COPERNICUS trial, the NT-proBNP levels in
the carvedilol groupwere decreased by 15%, with a heart rate reduction
of 12.5 bpm [22]. In the CARMEN trial [23], both NT-proBNP and BNP
were signiﬁcantly reduced after 6 months of carvedilol treatment
(NT-proBNP,−22% and BNP,−20%), whichmight reﬂect reversed car-
diac remodeling. In the J-CHF study, the BNPwas relatively decreased as
much as 60% from baseline with no differences between doses of carve-
dilol, showing an essential effect on reverse remodeling even at a low
dose of carvedilol.
Genetic variations cause differences in individual responses and may
also serve as genetic predictors for long-term outcomes [24–26]. In the
J-CHF study, the OPN polymorphism, but not the beta1AR polymor-
phisms (Ser49Gly and Arg389Gly) and alpha (2C) Del, was signiﬁcantly
associated with event-free survival with carvedilol treatment among
237 heart failure-associated polymorphisms. Osteopontin plays a major
role in regulating extracellularmatrix proteins, including collagen and ﬁ-
bronectin. Increased OPN expression parallels cardiac remodeling and
heart failure [27]. Myocardial biopsies from patients with advanced
heart failure show higher expression of myocardial OPN than those of
healthy subjects with concomitant cardiac ﬁbrosis [28]. The OPN G-156
del polymorphism is located in the RUNX2 binding site, and an in vitro
promoter assay revealed that the−156G allele shows higher promoter
activity than the −156del allele in the presence of the Runt-related
transcription factor 2 (RUNX2) expression vector [29]. However, beta-
blockers have less efﬁcacy in patients with relatively severe myocardial
ﬁbrosis [30]. Taking these observations together, we assume that pa-
tients with the OPN-156 G allele have a higher OPN expression, more
myocardial ﬁbrosis, and are less responsive to carvedilol than OPN-del
homozygous patients. Besides J-CHF study, pharmaco-genomic analy-
ses were performed in different cohorts to examine beforehand poly-
morphisms associated with responsiveness to beta-blocker in patients
with heart failure. In other cohorts having similar sample size, OPN
G-156 del genotype was signiﬁcantly associated with responsiveness
to carvedilol (Data not shown). In J-CHF, about one-third of patients
had the −156G allele. OPN may be a genetic marker that predicts the
morbidity and mortality of CHF patients, although our present ﬁndings
are hypothesis-generating, and a large-scale trial is needed to conﬁrm
this hypothesis.
Based on the J-CHF results, the long-term effect of carvedilol in pa-
tients with CHF does not depend strictly on the target dose, and the
relation between effect and dose, if any, is small. A higher dose can re-
sult in better outcomes, which may be offset by more adverse events.
The optimal dose in terms of safety and efﬁcacy should be determined
by individual responsiveness, balanced by the impact on quality of
life. Decreases in heart rate and/or BNP are effective as surrogate
and predictive variables of improvement. In particular, initial heart
rate reduction is an easily measured clinical parameter to evaluate
the responsiveness to carvedilol.
4.1. Limitations
The present study had several limitations. First, because of the
PROBE design and ethical considerations, the J-CHF study did not have
a placebo group, although the MUCHA study revealed that 5 mg and
20 mg of carvedilol showed beneﬁcial effects on morbidity relative to
the placebo. Considering themagnitude of the increases in EF and the de-
creases in heart rate and BNP, each dose could exert beneﬁcial responses
in patients with systolic dysfunction. Second, the J-CHF study might be
too small and of insufﬁcient duration to determine the optimal carvedilol
dose. In clinical practice, beta-blocker doses are substantially lower than
the doses in clinical trials and those recommended by guidelines in Japan
andWestern countries. Thus, a large study is warranted to elucidate the
optimal doses for populationswith different ethnic/genetic backgrounds.
Despite these limitations, the present study provides clinically important
ﬁndings regarding the relationship between carvedilol use and outcomes
in a large, representative dataset of CHF patients.
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In conclusion, a low carvedilol dose is effective if the heart rate has
been reduced and the J-CHF study suggests that carvedilol therapy
should be guided by reductions in plasma BNP and/or heart rate, i.e.
initial heart rate reduction, to obtain optimal safety and efﬁcacy. An
OPN polymorphism is a surrogate genetic marker for long-term
event-free survival. Further research is needed to determine ethnic
and racial differences in response to beta-blocker therapy.
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